If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.

Vifor Pharma to pay £23m to NHS after competition probe into misleading claims - The competition watchdog was investigating ...

After recently taking steps to undo messaging about a rival product in the European Union, CSL Vifor is carrying its amends ...

The CMA has secured an offer of £23m from Vifor Pharma to the NHS, as part of a wider package, to address concerns that ...

This case marks the first time the CMA has investigated misleading claims under its competition law enforcement powers. The ...

Vifor Pharma has gained final European marketing approval for its hyperkalaemia treatment Veltassa. The approval is a major milestone for the Switzerland-headquartered speciality pharma company ...

Vifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency drugs. The partnership expands Vifor Pharma’s cooperation with Fresenius ...

The U.K. Competition Appeal Tribunal (CAT) has imposed its own fines on Pfizer and Flynn Pharma for abusing their dominant positions by ...

Telefonica tops forecast with 79% surge in Q1 profit May 9, 2024 Vifor Pharma has offered to launch a marketing campaign to address any damage caused by its criticisms of a rival to its key drug ...

Previously, he was CFO at Vifor Pharma where he was instrumental in the separation of Galenica from Vifor Pharma onto the Swiss Exchange in 2017. During his career, he also served as CFO of Evotec ...

He has over 40 years of experience in the healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and past global head of the Pharmaceutical Division of Bayer AG. David has chaired ...